MARC Record from Library of Congress

LEADER: 03687cam a22003854a 4500
001 2011034552
003 DLC
005 20120521151028.0
008 110815s2011 nyu b 000 0 eng
010 $a 2011034552
020 $a9780525952404 (hardback)
035 $a(DNLM)101566935
040 $aDNLM/DLC$cDLC$dDLC
042 $apcc
050 00 $aHD9666.5$b.S54 2011
060 10 $aQV 736
082 00 $a338.4/76153$223
100 1 $aSharp, Kathleen.
245 10 $aBlood feud :$bthe man who blew the whistle on one of the deadliest prescription drugs ever /$cKathleen Sharp.
260 $aNew York :$bDutton/Penguin Group,$cc2011.
300 $aviii, 424 p. ;$c24 cm.
504 $aIncludes bibliographical references.
505 0 $aMeet and greet -- The deal -- Medicine road -- Raise the stakes -- The cancer indication -- Chosen one -- The deposition -- On the border -- Blues -- Quality of life -- Gaslighting -- The overdose plan -- The millionaires' club -- "Strength for living" -- Code mistress -- The arbitrator -- For the king -- Black ops -- The eleventh hour -- Twice saved -- Miracle gro -- Brothers -- The powers that spin -- The burden.
520 $a"Blood Feud is the electrifying true tale of Big Pharma's power, regulatory weakness, and the terrifying vulnerability of millions of innocent patients. THE PLAYERS The Drug: Procrit An anti-anemia drug, this miraculous blood booster was one of the first biotech blockbusters. Developed by Amgen and licensed to a Johnson & Johnson company, the drug was sold by the two companies under the brand names Procrit, Epogen, and Arenesp. The Underdog: Mark Duxbury, Drug Salesman Duxbury was the gung-ho salesman for the new biotech division of J&J, an irrepressible character full of jokes. In the early 1990s, he set out to spread the benefits of Procrit, and became a true believer and top seller. But he and his peers were told to steal business from J&J's partner, Amgen. Then came the marketing studies, the off-invoice rebates, doctor payments, and off-label claims. Duxbury tried to stop some of these ruthless programs, but was fired on trumped-up charges. He tried anything to warn the public: testifying in a secret arbitration, joining a class action effort, and filing a whistleblower suit. But he was thwarted at nearly every turn-until the surprising end. The Best Friend: Dean McClellan, Drug Legend Dean McClellan was Duxbury's friendly rival. He tried to beat his buddy's record and wound up selling $170 million worth of the drug, becoming a legend. When Duxbury got fired, McClellan tried to distance himself. But as news of Procrit's deadly power started to surface, McClellan agreed to hand over thousands of damning documents and help his friend blow the whistle on J&J. The Crusader: Jan Schlichtmann, Esq. Remember Jan Schlichtmann, protagonist of the best-selling book and Oscar nominated movie, A Civil Action? When he learned of Duxbury's mission, he felt the old fire rising in his belly and signed on. Now, he's gambling on yet another long shot, trying to fight on behalf of not just millions of cancer patients, but for every American who overpays for health-care"--Provided by publisher.
600 12 $aDuxbury, Mark.
600 12 $aMcClellan, Dean.
600 12 $aSchlichtmann, Jan.
610 22 $aAmgen Inc.
610 22 $aJohnson and Johnson, inc.
650 12 $aDrug Industry$xeconomics$zUnited States.
650 12 $aEpoetin Alfa$xeconomics$zUnited States.
650 22 $aAnemia$xdrug therapy$zUnited States.
650 22 $aEpoetin Alfa$xadverse effects$zUnited States.
650 22 $aMarketing of Health Services$xeconomics$zUnited States.
650 22 $aWhistleblowing$zUnited States.